PepGen DSMB recommends advancing PGN-EDODM1 to 12.5 mg/kg; Q2 net loss $17.8M

PepGen Inc.

DSMB recommends advancing FREEDOM2-DM1 to 12.5 mg/kg highest dose cohort; no protocol changes.
DSMB also approves OLE dose escalation from 5 mg/kg to 10 mg/kg; 6 of 8 from 5 mg/kg cohort enrolled in OLE.
10 mg/kg cohort fully enrolled, 7 of 8 completed dosing; data expected November 2026.
Q2 2026 net loss $17.8M ($0.26 per share) vs $23.1M ($0.70) in Q2 2025; R&D expenses $12.5M.
Cash $117.2M as of June 30, 2026; sufficient into Q4 2027.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.